BHO doesn't want to govern under the Constitution. He wants to be a celebrity dictator. He has denigrated the Presidency more than any other man. What a national nightmare he is.
The way CLDX has traded since December, with its volatile ascending sawtooth pattern, it could easily swing back up to $33-$34 over the next two weeks, then fall back down over the subsequent two weeks to $25-$26.
Every trader eying CLDX has noted the same pattern on the chart that I'm talking about, and they're looking to profit from it.
Yes, CLDX is undervalued. It should be trading in the 30s minimum right now. I think there's a strong possibility that the selling has been an overreaction to the cc or a deliberate manipulation down to the 200DMA for technical reasons.
I bought some shares today for a trade after the price nearly touched the 200DMA and then bounced off of it.
At this low price, CLDX is once again a buy for new shares and a hold for long-term shares. Closer to $30 it becomes a pure hold again until there is a major news announcement.
CLDX could easily double on good news about the ReACT trial or about 1127, but we don't know when that will occur.
The latest unconstitutional change to the law is a buried HHS directive that the individual mandate will be abolished for two more years.
Obamacare is a disaster. It's not a law anymore, it's whatever Obama says it is until he changes his mind again. That's not how we govern in America.
Time for Obamacare to be repealed, and time for Obama to be impeached. Time for Americans to punish the Democrats hard in the next election.
+++ObamaCare’s implementers continue to roam the battlefield and shoot their own wounded, and the latest casualty is the core of the Affordable Care Act—the individual mandate. To wit, last week the Administration quietly excused millions of people from the requirement to purchase health insurance or else pay a tax penalty.
This latest political reconstruction has received zero media notice, and the Health and Human Services Department didn’t think the details were worth discussing in a conference call, press materials or fact sheet. Instead, the mandate suspension was buried in an unrelated rule that was meant to preserve some health plans that don’t comply with ObamaCare benefit and redistribution mandates. Our sources only noticed the change this week.
That seven-page technical bulletin includes a paragraph and footnote that casually mention that a rule in a separate December 2013 bulletin would be extended for two more years, until 2016. Lo and behold, it turns out this second rule, which was supposed to last for only a year, allows Americans whose coverage was cancelled to opt out of the mandate altogether.
But people can also qualify for hardships for the unspecified nonreason that “you experienced another hardship in obtaining health insurance,” which only requires “documentation if possible.” And yet another waiver is available to those who say they are merely unable to afford coverage, regardless of their prior insurance. In a word, these shifting legal benchmarks offer an exemption to everyone who conceivably wants one.
The information below is from Linked In. Shows that Rosenberg is newly hired in oncology marketing at Celldex as of January 2014. He left Bristol Myers after many years there of advancing in the ranks. I was looking for information about who had been hired in Celldex's newly created marketing division, and he was a name that came up as a recent hire. He must have seen a golden opportunity with Celldex in order to be persuaded to leave a promising career with Bristol Myers.
Michael Rosenberg's Overview
Associate Director Oncology Marketing at Celldex Therapeutics
Senior Product Manager, Professional Marketing, ORENCIA (Rheumatoid Arthritis) at Bristol-Myers Squibb
Product Manager, Orencia Marketing (Professional) at Bristol-Myers Squibb, Princeton, New Jersey
Manager; Learning and Development / Sales Training at Bristol-Myers Squibb, Princeton, New Jersey
Associate Manager, Learning and Development (Immunoscience) at Bristol-Myers Squibb, Princeton, New Jersey
Senior Territory Business Manager at Bristol-Myers Squibb, Princeton, New Jersey
Michael Rosenberg's Experience
Associate Director Oncology Marketing
Public Company; 51-200 employees; CLDX; Biotechnology industry
January 2014 – Present (3 months) New Jersey
Marucci made the following remarks at the beginning of his overview of the company's accomplishments. Note that he says "excellent progress" in patient accrual and anticipated complete enrollment in mid-2014, which is only months away. Of particular noteworthiness is his statement that, if Rindo is approved, it will already be "well-positioned in the marketplace." Marucci is communicating optimism regarding accrual, approval and an immediately available in-place network for sales. In otherwords, the Rindo runway is built; all that remains is for the plane to be approved for flight and it can immediately be launched.
"Let’s start with a quick review of the major accomplishments in 2013. The first is rindo, a targeted immunotherapeutic for the treatment of patients with EGFRv3 positive glioblastoma. On Slide 3, in 2013 we made excellent progress in accruing to the Phase III Act IV registration study of rindo in front-line glioblastoma. We continue to enroll newly diagnosed patients across more than 200 sites in 24 countries. While this broad reach has been important to the recruitment efforts, particularly for an orphan disease, we also think it will play a critical role in supporting potential drug launch. We feel confident that we have put rindo into the hands of a significant number of physicians worldwide who treat brain cancer and that with positive results rindo will be well positioned in the marketplace. We continue to anticipate completion of enrollment in mid-2014 and we will keep you updated as we get closer to this milestone."
Thank you for the encouragement, and you make correct observations and deductions. I share your optimism. Cold feet I do not have; I am heavily invested in the company already.
I agree, but I'm no longer a "strong buy" guy. It would take news about robust, hard RESULTS or a major partnership to return me to being a "strong buy" guy. News about more trials is a positive sign that things are going in a good direction, but that is not a strong reason to buy if you haven't bought already at a much lower share price. So I'm now a "hold" guy. After ASCO I might return to being a "strong buy" guy.
If Celldex were to sell CDX-1135 to Alexion for $500 million, it wouldn't need to partner anything else it's working on. OTOH, if CDX-1135 is that promising, you don't want to let it go for even that much money. OTOH, it's not doing any good for the company now nor will it in the near future, so selling it seems acceptable.
I was saying, if Varli is not a SUPERSTAR within six months then it would be prudent, less risky and sound management to partner it.
If AM plays the waiting game then the market will wonder whether a high valuation for Varli is warranted. The way AM handled 1135 taints his credibility slightly, and it will color the way the market responds to silence or merely verbal reassurances regarding Varli.
I agree. It would be irresponsible to take Varli to the brink solo unless the phase-1 data are PHENOMENAL and are presented to widespread acclaim at ASCO. If Varli is not a SUPERSTAR
Yes, I agree that Marucci needs to deliver something significant this year, preferably 1H 2014.
If Celldex doesn't present impressive results for Varli at ASCO, that would be a warning sign that perhaps Varli will not live up to management's early excitement.
Okay, thanks for the reassurance. I was worried I had overlooked a subsequent posting of yours.
No rush. I hope you realize how much many of us deeply appreciate your analyses.
you will definitely see a strong rally in CLDX preceding the conference.
And there are good reasons to believe that the Varli trials will be considered worthy of such attention as the spotlight focuses more on cancer immunotherapy as the next wave in treating cancer.
I don't know whether management mentioned the possibility that updated Rindo data from the ReACT trial could be presented at ASCO, but that would be another exciting prospect as Rindo succeeds where Avastin has failed.
Thanks, but those were more synopses than comments. Long stated that he would provide "detailed notes later", and that is what I was asking about: had I missed his posting of those detailed notes and comments as opposed to the summary that he had provided.
I'm interested in long's analysis.
I know I'm far from the only one who looks forward to his cogent and insightful analyses whenever there is a significant presentation by management.
Thank you, long, for your generous and selfless assistance to fellow "long_cldx" board participants.
If I happened to miss the comments, would someone please bump the post to the top of the message board?
Stagnant is okay with me for now because of the outsized gains already and the potential for outsized, outperforming gains later this year and in the years ahead. Holding qualifies you for the tax-advantaged long-term capital gain status and permits you to defer taxation into the future while eventually earning returns on capital that you would have had to surrender to the taxman if you sold.
Trading actively is not all it's cracked up to be. The "Fast Money" crowd on CNBC is a joke. Buy and hold is a much better strategy, especially when you have identified a high-growth opportunity.